-
公开(公告)号：US20210024890A1
公开(公告)日：2021-01-28
申请号：US16936874
申请日：2020-07-23
发明人： Chengfei Pu , Wensheng Wang , Dongqi Chen , Lei Xiao
IPC分类号： C12N5/0783 , C07K14/705 , C07K16/28 , C07K14/725
摘要： The present disclosure describes a method of producing T cells exhibiting an enhanced memory T cell phenotype, the method comprising: modulating a population of T cells to enhance the expression and/or function of high mobility group protein Y (HMGY). In embodiments, the method may include introducing a polynucleotide encoding HMGY into a population of T cells, wherein expression of HMGY is higher in the population of T cells as compared to a population of T cells that are not introduced with the polynucleotide, and the memory T cell phenotype of the population of T cells is enhanced as compared to T cells that are not introduced with the polynucleotide. In embodiments, the method can also include introducing a polynucleotide encoding one or more genes associated with HMGY, for example, upstream or downstream of the signaling pathway associated with HMGY and/or a transcription factor associated with HMGY.
-
公开(公告)号：US20240058337A1
公开(公告)日：2024-02-22
申请号：US18450545
申请日：2023-08-16
发明人： Lei Xiao , Zhao Wu , Chengfei Pu , Zhiyuan Cao , Dongqi Chen , Xiaobin Lu , Le Tian
IPC分类号： A61K31/506 , A61K39/395 , A61K39/00 , A61K31/573 , A61P35/00
CPC分类号： A61K31/506 , A61K39/3955 , A61K39/4631 , A61K31/573 , A61K39/4611 , A61K39/4612 , A61P35/00
摘要： The present disclosure relates to compositions and methods for reducing side effects and/or enhancing cancer treatment that use modified immune cells expressing chimeric antigen receptors (CARs) or modified T cell receptors (TCRs). The modified immune cells, such as T cells or NK cells, can express CARs or TCRs targeting solid tumor antigens, white blood cell antigens like CD19, or bispecific CARs/TCRs targeting both. The methods include administering dasatinib to reduce the side effects associated with CAR T or TCR therapy and/or enhance cancer treatment. The modified cells can co-express additional therapeutic agents like cytokines.
-
公开(公告)号：US20230226113A1
公开(公告)日：2023-07-20
申请号：US18194349
申请日：2023-03-31
发明人： Yang Li , Zhiyuan Cao , Wei Ding , Xianyang Jiang , Chengfei Pu , Le Tian , Christopher Ballas , Zhao Wu , Lei Xiao
IPC分类号： A61K35/17 , A61K47/69 , C07K14/725
CPC分类号： A61K35/17 , A61K47/6911 , C07K14/7051
摘要： The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFNγ.
-
公开(公告)号：US20230074145A1
公开(公告)日：2023-03-09
申请号：US17821706
申请日：2022-08-23
发明人： Zhiyuan Cao , Yuzhe Peng , Lei Xiao , Zhao Wu , Le Tian
IPC分类号： C07K16/40 , C07K14/725 , A61K35/17 , A61P35/00
摘要： The compositions and methods described herein are directed to treating solid tumors using CAR T therapy and/or antibodies targeting GCC. The compositions include CAR comprising an extracellular domain that binds GCC.
-
公开(公告)号：US20210077528A1
公开(公告)日：2021-03-18
申请号：US17023835
申请日：2020-09-17
发明人： Zhiyuan Cao , Chengfei Pu , Dongqi Chen , Wei Ding
IPC分类号： A61K35/17 , C07K14/725 , C07K14/705 , C07K16/30 , C07K16/40
摘要： Embodiments relate to a modified cell comprising a polynucleotide encoding a dominant negative form of Death receptor 5 (DR5). In embodiments, the modified cell further comprises a chimeric antigen receptor (CAR) and/or a modified TCR.
-
公开(公告)号：US20240307442A1
公开(公告)日：2024-09-19
申请号：US18571062
申请日：2022-06-16
发明人： Wei DING , Yang ZHAO , Guiting HAN , Yuzhe PENG , Xianyang JIANG , Zhiyuan CAO , Lei XIAO , Le TIAN
CPC分类号： A61K35/17 , A61K39/001112 , A61K39/4611 , A61K39/4631 , A61K39/464459 , A61K39/46446 , A61P37/04 , C07K16/2803 , C12N9/6408 , C12N9/641 , C12N9/6491 , A61K2239/13 , A61K2239/21 , A61K2239/22
摘要： Embodiments relate to a modified cell comprising a polynucleotide encoding an antigen binding molecule and a polynucleotide encoding an agent targeting one or more extracellular matrix (ECM) molecules. In embodiments, the polynucleotide encoding the agent comprises at least a nucleic acid encoding Cathepsin K (CK), a nucleic acid encoding Neutrophil Elastase (NE), or a nucleic acid encoding MMP7. In embodiments, the nucleic acid encoding NE comprises a nucleic acid encoding NE and a nucleic acid encoding a signaling domain of IL2. In embodiments, expression of the polynucleotide encoding the agent is regulated by hypoxia-inducible factor 1-alpha (HIF1α), nuclear factor of activated T-cells (NFAT), forkhead box P3 (FOXP3), or nuclear factor kappa B (NF-κB).
-
公开(公告)号：US12076343B2
公开(公告)日：2024-09-03
申请号：US17173504
申请日：2021-02-11
发明人： Chengfei Pu , Zhiyuan Cao , Zhao Wu , Lei Xiao
IPC分类号： A61K35/17 , C07K14/535 , C07K14/54 , C07K14/55
CPC分类号： A61K35/17 , C07K14/535 , C07K14/5412 , C07K14/5418 , C07K14/5434 , C07K14/5443 , C07K14/55
摘要： The present disclosure relates to compositions and methods for treating cancer. For example, a modified cell may include a polynucleotide comprising an NFAT promoter, a nucleotide sequence encoding therapeutic agent, and a nucleotide sequence encoding a VHL-interaction domain of HIF1α, wherein the therapeutic agent comprises, for example, IL-12, IL-6, and/or IFNγ.
-
公开(公告)号：US20240269182A1
公开(公告)日：2024-08-15
申请号：US18563764
申请日：2022-05-20
发明人： CHENGFEI PU , WENSHENG WANG , XIAOGANG SHEN , LE TIAN
IPC分类号： A61K35/17 , A61K39/00 , C07K14/705 , C07K14/725 , C07K14/73 , C07K16/30
CPC分类号： A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/464486 , C07K14/7051 , C07K14/70514 , C07K14/70517 , C07K16/30 , A61K2239/13 , A61K2239/21 , A61K2239/22 , A61K2239/57 , C07K2317/622 , C07K2319/02 , C07K2319/03
摘要： Embodiments of the present disclosure relate to a polynucleotide encoding a CAR comprising a cytoplasmic domain of CD4, or a CAR comprising SEQ ID NO: 17 in its intracellular domain, and the cytoplasmic domain of CD4 is located between a transmembrane domain of the CAR and a signaling or stimulatory domain, for example, CD3 zeta domain.
-
公开(公告)号：US20230293691A1
公开(公告)日：2023-09-21
申请号：US18008911
申请日：2021-06-09
发明人： Lei Xiao , Chengfei Pu , Zhiyuan Cao , Xiaogang Shen , Dongqi Chen , Beibei Jia , Le Tian
IPC分类号： A61K39/00 , C07K16/30 , A61P35/00 , A61P37/04 , C07K14/725 , C07K14/705
CPC分类号： A61K39/464486 , A61K39/4611 , A61K39/4631 , A61P35/00 , A61P37/04 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K16/30 , A61K38/00 , A61K2039/505 , C07K2319/33
摘要： The present disclosure relates to compositions and methods for treating a subject having cancer associated with melanoma-associated antigen 4 (MAGE-A4) peptide. The disclosure includes the embodiments relate to a chimeric antigen receptor (CAR) that binds MAGE-A4 peptide, a polynucleotide encoding a CAR that binds the MAGE-A4 peptide, a modified cell comprising a CAR that binds the MAGE-A4 peptide, and a population of modified cells comprising a CAR that binds the MAGE-A4 peptide.
-
公开(公告)号：US20230201440A1
公开(公告)日：2023-06-29
申请号：US17998127
申请日：2021-05-07
发明人： Lei Xiao , Zhiyuan Cao , Zhao Wu , Chengfei PU , Xiaogang Shen , Haiyang Tang , Le Tian
CPC分类号： A61M1/362 , A61M1/3609 , A61M1/3692 , C07K16/2809 , C07K16/2818 , C12M41/36 , A61M2205/3368 , A61M2205/3324
摘要： The present disclosure relates to a system for immune therapy, the system comprising a sample processing module configured to obtain whole blood from a subject; a cell incubation module configured to activate blood cells of the whole blood and/or introduce a vector into the blood cells of the whole blood; and a cell infusion module configured to infuse at least a portion of the whole blood to the subject, wherein the blood cells comprise CD3+ cells, NK cells, myeloid cells, and neutrophils.
-
-
-
-
-
-
-
-
-
搜索结果
37 条记录 (耗时 0.014 秒)
